Suppr
超能文献

A call to arms against ultra-rare diseases.

作者信息

Crooke Stanley T

机构信息

n-Lorem and Ionis Pharmaceuticals, Carlsbad, CA, USA.

出版信息

Nat Biotechnol. 2021 Jun;39(6):671-677. doi: 10.1038/s41587-021-00945-0.

DOI:10.1038/s41587-021-00945-0

PMID:34089038

Abstract

摘要

相似文献

A call to arms against ultra-rare diseases.

Nat Biotechnol. 2021 Jun;39(6):671-677. doi: 10.1038/s41587-021-00945-0.

Making dollars and sense of antisense.

Expert Opin Investig Drugs. 2005 Feb;14(2):111-5. doi: 10.1517/13543784.14.2.111.

Creating more paths to hope.

Newsweek. 2004 Dec 6;144(23):80.

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.

N Engl J Med. 2019 Oct 24;381(17):1644-1652. doi: 10.1056/NEJMoa1813279. Epub 2019 Oct 9.

The cost of getting personal.

Nat Med. 2019 Dec;25(12):1797. doi: 10.1038/s41591-019-0700-3.

Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges.

Nucleic Acid Ther. 2014 Feb;24(1):1-3. doi: 10.1089/nat.2014.1500.

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.

Nucleic Acid Ther. 2017 Apr;27(2):67-69. doi: 10.1089/nat.2017.0665. Epub 2017 Feb 21.

Spinal muscular atrophy approval boosts antisense drugs.

Nat Biotechnol. 2017 Feb 8;35(2):99-100. doi: 10.1038/nbt0217-99.

Their lives in their hands.

Nat Biotechnol. 2019 Nov;37(11):1255-1260. doi: 10.1038/s41587-019-0303-z.

Antisense drugs for rare and ultra-rare genetic neurological diseases.

Neuron. 2023 Aug 16;111(16):2465-2468. doi: 10.1016/j.neuron.2023.05.027. Epub 2023 Jun 23.

引用本文的文献

Chemical Modifications in Nucleic Acid Therapeutics.

Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.

Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells.

Nucleic Acids Res. 2025 Jul 8;53(13). doi: 10.1093/nar/gkaf658.

Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.

Mol Ther Methods Clin Dev. 2025 Jan 17;33(1):101403. doi: 10.1016/j.omtm.2024.101403. eCollection 2025 Mar 13.

Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.

Mol Ther Nucleic Acids. 2024 Dec 22;36(1):102432. doi: 10.1016/j.omtn.2024.102432. eCollection 2025 Mar 11.

Enriched phenotypes in rare variant carriers suggest pathogenic mechanisms in rare disease patients.

BioData Min. 2025 Jan 17;18(1):6. doi: 10.1186/s13040-024-00418-5.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Nat Rev Drug Discov. 2025 Jan;24(1):40-56. doi: 10.1038/s41573-024-01059-3. Epub 2024 Nov 4.

Antisense oligonucleotides and their applications in rare neurological diseases.

Front Neurosci. 2024 Sep 23;18:1414658. doi: 10.3389/fnins.2024.1414658. eCollection 2024.

The expanding application of antisense oligonucleotides to neurodegenerative diseases.

J Clin Invest. 2024 Oct 1;134(19):e186116. doi: 10.1172/JCI186116.

Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector's contributions to drug development and access.

Front Pharmacol. 2024 Aug 12;15:1441807. doi: 10.3389/fphar.2024.1441807. eCollection 2024.

Antisense Oligonucleotide Therapy for Calmodulinopathy.

Circulation. 2024 Oct 8;150(15):1199-1210. doi: 10.1161/CIRCULATIONAHA.123.068111. Epub 2024 Aug 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

A call to arms against ultra-rare diseases.

Nat Biotechnol. 2021 Jun;39(6):671-677. doi: 10.1038/s41587-021-00945-0.

Making dollars and sense of antisense.

Expert Opin Investig Drugs. 2005 Feb;14(2):111-5. doi: 10.1517/13543784.14.2.111.

Creating more paths to hope.

Newsweek. 2004 Dec 6;144(23):80.

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.

N Engl J Med. 2019 Oct 24;381(17):1644-1652. doi: 10.1056/NEJMoa1813279. Epub 2019 Oct 9.

The cost of getting personal.

Nat Med. 2019 Dec;25(12):1797. doi: 10.1038/s41591-019-0700-3.

Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges.

Nucleic Acid Ther. 2014 Feb;24(1):1-3. doi: 10.1089/nat.2014.1500.

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.

Nucleic Acid Ther. 2017 Apr;27(2):67-69. doi: 10.1089/nat.2017.0665. Epub 2017 Feb 21.

Spinal muscular atrophy approval boosts antisense drugs.

Nat Biotechnol. 2017 Feb 8;35(2):99-100. doi: 10.1038/nbt0217-99.

Their lives in their hands.

Nat Biotechnol. 2019 Nov;37(11):1255-1260. doi: 10.1038/s41587-019-0303-z.

Antisense drugs for rare and ultra-rare genetic neurological diseases.

Neuron. 2023 Aug 16;111(16):2465-2468. doi: 10.1016/j.neuron.2023.05.027. Epub 2023 Jun 23.

引用本文的文献

Chemical Modifications in Nucleic Acid Therapeutics.

Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.

Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells.

Nucleic Acids Res. 2025 Jul 8;53(13). doi: 10.1093/nar/gkaf658.

Ensuring patient access to gene therapies for rare diseases: Navigating reimbursement and coverage challenges.

Mol Ther Methods Clin Dev. 2025 Jan 17;33(1):101403. doi: 10.1016/j.omtm.2024.101403. eCollection 2025 Mar 13.

Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder.

Mol Ther Nucleic Acids. 2024 Dec 22;36(1):102432. doi: 10.1016/j.omtn.2024.102432. eCollection 2025 Mar 11.

Enriched phenotypes in rare variant carriers suggest pathogenic mechanisms in rare disease patients.

BioData Min. 2025 Jan 17;18(1):6. doi: 10.1186/s13040-024-00418-5.

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap.

Nat Rev Drug Discov. 2025 Jan;24(1):40-56. doi: 10.1038/s41573-024-01059-3. Epub 2024 Nov 4.

Antisense oligonucleotides and their applications in rare neurological diseases.

Front Neurosci. 2024 Sep 23;18:1414658. doi: 10.3389/fnins.2024.1414658. eCollection 2024.

The expanding application of antisense oligonucleotides to neurodegenerative diseases.

J Clin Invest. 2024 Oct 1;134(19):e186116. doi: 10.1172/JCI186116.

Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector's contributions to drug development and access.

Front Pharmacol. 2024 Aug 12;15:1441807. doi: 10.3389/fphar.2024.1441807. eCollection 2024.

Antisense Oligonucleotide Therapy for Calmodulinopathy.

Circulation. 2024 Oct 8;150(15):1199-1210. doi: 10.1161/CIRCULATIONAHA.123.068111. Epub 2024 Aug 19.

Suppr超能文献

A call to arms against ultra-rare diseases.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译